{
  "pmcid": "8135056",
  "sha256": "b2d63f683e4e9fbf3c40fe83371c34e81bf5a525236c91667e13818b8ee9e636",
  "timestamp_utc": "2025-11-09T16:16:51.709868+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.465828913368693,
    "reading_ease": 20.458727050183626,
    "word_count": 387
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "In this randomized phase 2 trial in patients diagnosed with resectable CPM"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "An open-label, parallel-group phase 2 randomized clinical trial in all 9 Dutch tertiary centers for the surgical treatment of CPM enrolled participants between June 15, 2017, and January 9, 2019."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were patients with pathologically proven isolated resectable CPM who did not receive systemic therapy within 6 months before enrollment."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Randomization to perioperative systemic therapy or CRS-HIPEC alone."
      },
      "Objective": {
        "score": 1,
        "evidence": "To assess the feasibility and safety of perioperative systemic therapy in patients with resectable CPM and the response of CPM to neoadjuvant treatment."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Proportions of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative morbidity."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "An open-label, parallel-group phase 2 randomized clinical trial"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "In 79 patients included in the analysis (43 [54%] men; mean [SD] age, 62 [10] years)"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analyses were done modified intention-to-treat in patients starting neoadjuvant treatment (experimental arm) or undergoing upfront surgery (control arm)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "experimental (n = 37) and control (n = 42) arms did not differ significantly regarding the proportions of macroscopic complete CRS-HIPEC (33 of 37 [89%] vs 36 of 42 [86%] patients; risk ratio, 1.04; 95% CI, 0.88-1.23; P = .74) and Clavien-Dindo grade 3 or higher postoperative morbidity (8 of 37 [22%] vs 14 of 42 [33%] patients; risk ratio, 0.65; 95% CI, 0.31-1.37; P = .25)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No treatment-related deaths occurred."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT02758951"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}